Kaiyang Ding

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Luis Malpica, Qingqing Cai et al. · The Lancet Oncology · 2023 · 55 citations

Medicine, Oncology, Pharmacology +13

Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

Huiqiang Huang, Rong Tao, Siguo Hao et al. · Journal of Clinical Oncology · 2023 · 48 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pre‐engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies

Xingbing Wang, Huilan Liu, Lailing Li et al. · European Journal Of Haematology · 2011 · 38 citations

Medicine, Dermatology, Hematology +15

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

Wei Xu, Keshu Zhou, Tingyu Wang et al. · American Journal of Hematology · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria

Lu Zhang, Hongling Peng, Hao Li et al. · The Lancet Regional Health - Western Pacific · 2023 · 36 citations · Full text

Life Sciences, Internal Medicine, Pathology +12